Veeva Systems (VEEV) Unveils Falcon, An Agentic Platform Built For Life Sciences Drug Development Processes Veeva Systems Inc. (NYSE:VEEV), with significant hedge fund interest, ranks among the 10 best SaaS stocks to buy according to hedge funds.
As of Q1 2026, 62 hedge funds held bullish positions in the stock, representing $2.95 billion in aggregate value, as per Insider Monkey data
This week, Veeva Systems Inc. (NYSE:VEEV) is accelerating its efforts to deepen its footprint across the life sciences industry, securing major global CRM commitments while rolling out new AI-driven automation tools for drug development. On May 28, 2026, Veeva Systems Inc. (NYSE:VEEV) announced that Kindeva, a contract development and manufacturing organization, is adopting Veeva Quality Cloud to unify its global network of sites onto a single platform. The deployment includes Veeva QualityDocs, Veeva QMS, Veeva Training, and Veeva LearnGxP.
Kindeva said the platform will standardize quality assurance and training processes, eliminate data silos, and support growth across regions and therapeutic areas. That announcement followed a pair of CRM commitments disclosed on May 27, 2026. Merck KGaA (Darmstadt, Germany) committed globally to Veeva Vault CRM, with the company’s CIO citing consistent processes and data connectivity as priorities.